The new law will expand access for Medi-Cal patients who receive a complex cancer diagnosis and represents a critical first step in fulfilling the promise of the California Cancer Patients Bill of Rights, a resolution adopted by the legislature in 2021.
Selected coverage from the Quality Cancer Care Alliance (QCCA) Summer 2022 National Leadership Summit, the National Comprehensive Cancer Network (NCCN) Fall Policy Summit, and the American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved.
Coverage from the New York City presentation of the Institute for Value-Based Medicine, co-chaired by Emeline Aviki, MD, MBA, of Memorial Sloan Kettering Cancer Center (MSKCC), and Robert Daly, MD, MBA, medical oncologist and lung cancer specialist at MSKCC.
A featured presentation at the Irvine, California, meeting of the Institute for Value-Based Medicine discussed how a patient with long-term HIV was cured through a transplant.
Coverage from the Irvine, California, meeting of the Institute for Value-Based Medicine, chaired by Joseph Alvarnas, MD, vice president for government affairs at City of Hope and chief clinical advisor, AccessHope.
Coverage from the Minnesota meeting of the Institute for Value-Based Medicine, chaired by Rajini Katipamula-Malisetti, MD, vice president of medical oncology at Minnesota Oncology.
Coverage from the Atlanta meeting of the Institute for Value-Based Medicine, chaired by Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services, Emory Healthcare and Emory Winship Cancer Institute.
Featured coverage from the 70th Annual Roy A. Bowers Pharmaceutical Conference, held September 19, 2022. The theme for the 2022 conference was Innovation Through Crisis: Redefining Health Care Delivery.
Implications of Telehealth Use on the Future of Oncology Care
The Enhancing Oncology Model (EOM) will be the successor to the Oncology Care Model.
The National Comprehensive Cancer Network recommendations come as the FDA weighs an indication in chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) for zanubrutinib.
Wayne Winegarden, PhD, of the Pacific Research Institute, explains the harm that white bagging policies cause health systems and how replacing them with new measures to boost market competition could help patients.
